MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- GLENMARK PHARMA - ABBOTT INDIA
GLENMARK PHARMA vs ABBOTT INDIA - Comparison Results
GLENMARK PHARMA Change
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
ABBOTT INDIA 
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Current Valuations
| GLENMARK PHARMA | ABBOTT INDIA | GLENMARK PHARMA/ ABBOTT INDIA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 11.4 | 56.1 | 20.3% | View Chart |
| P/BV | x | 1.6 | 13.5 | 12.0% | View Chart |
| Dividend Yield | % | 0.6 | 0.5 | 121.9% |
Financials
 GLENMARK PHARMA  ABBOTT INDIA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| GLENMARK PHARMA Mar-19 |
ABBOTT INDIA Mar-19 |
GLENMARK PHARMA/ ABBOTT INDIA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 712 | 8,834 | 8.1% | |
| Low | Rs | 484 | 5,458 | 8.9% | |
| Sales per share (Unadj.) | Rs | 349.6 | 1,731.1 | 20.2% | |
| Earnings per share (Unadj.) | Rs | 32.8 | 211.9 | 15.5% | |
| Cash flow per share (Unadj.) | Rs | 44.3 | 219.9 | 20.2% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 65.00 | 3.1% | |
| Dividend yield (eoy) | % | 0.3 | 0.9 | 36.8% | |
| Book value per share (Unadj.) | Rs | 198.6 | 945.2 | 21.0% | |
| Shares outstanding (eoy) | m | 282.17 | 21.25 | 1,327.9% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.7 | 4.1 | 41.4% | |
| Avg P/E ratio | x | 18.2 | 33.7 | 54.1% | |
| P/CF ratio (eoy) | x | 13.5 | 32.5 | 41.5% | |
| Price / Book Value ratio | x | 3.0 | 7.6 | 39.8% | |
| Dividend payout | % | 6.1 | 30.7 | 19.9% | |
| Avg Mkt Cap | Rs m | 168,625 | 151,848 | 111.0% | |
| No. of employees | `000 | 12.0 | 3.5 | 345.4% | |
| Total wages/salary | Rs m | 20,561 | 4,356 | 472.0% | |
| Avg. sales/employee | Rs Th | 8,196.0 | 10,555.5 | 77.6% | |
| Avg. wages/employee | Rs Th | 1,708.1 | 1,249.9 | 136.7% | |
| Avg. net profit/employee | Rs Th | 768.5 | 1,292.2 | 59.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 98,655 | 36,786 | 268.2% | |
| Other income | Rs m | 2,081 | 1,133 | 183.7% | |
| Total revenues | Rs m | 100,736 | 37,919 | 265.7% | |
| Gross profit | Rs m | 15,858 | 6,047 | 262.2% | |
| Depreciation | Rs m | 3,259 | 169 | 1,926.2% | |
| Interest | Rs m | 3,346 | 23 | 14,870.7% | |
| Profit before tax | Rs m | 11,335 | 6,989 | 162.2% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 1,672 | 0 | - | |
| Tax | Rs m | 3,756 | 2,485 | 151.2% | |
| Profit after tax | Rs m | 9,250 | 4,503 | 205.4% | |
| Gross profit margin | % | 16.1 | 16.4 | 97.8% | |
| Effective tax rate | % | 33.1 | 35.6 | 93.2% | |
| Net profit margin | % | 9.4 | 12.2 | 76.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 66,968 | 27,610 | 242.6% | |
| Current liabilities | Rs m | 40,211 | 8,569 | 469.3% | |
| Net working cap to sales | % | 27.1 | 51.8 | 52.4% | |
| Current ratio | x | 1.7 | 3.2 | 51.7% | |
| Inventory Days | Days | 83 | 60 | 138.4% | |
| Debtors Days | Days | 81 | 27 | 296.4% | |
| Net fixed assets | Rs m | 33,322 | 1,057 | 3,152.8% | |
| Share capital | Rs m | 282 | 213 | 132.8% | |
| "Free" reserves | Rs m | 55,770 | 19,873 | 280.6% | |
| Net worth | Rs m | 56,052 | 20,086 | 279.1% | |
| Long term debt | Rs m | 35,738 | 0 | - | |
| Total assets | Rs m | 132,888 | 29,409 | 451.9% | |
| Interest coverage | x | 4.4 | 311.6 | 1.4% | |
| Debt to equity ratio | x | 0.6 | 0 | - | |
| Sales to assets ratio | x | 0.7 | 1.3 | 59.4% | |
| Return on assets | % | 9.5 | 15.4 | 61.6% | |
| Return on equity | % | 16.5 | 22.4 | 73.6% | |
| Return on capital | % | 17.8 | 34.9 | 51.0% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 62,998 | 369 | 17,074.6% | |
| Fx outflow | Rs m | 22,859 | 4,918 | 464.8% | |
| Net fx | Rs m | 40,140 | -4,549 | -882.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 13,242 | 4,991 | 265.3% | |
| From Investments | Rs m | -6,990 | -2,570 | 272.0% | |
| From Financial Activity | Rs m | -7,387 | -1,428 | 517.3% | |
| Net Cashflow | Rs m | -2,971 | 993 | -299.1% | |
Share Holding
| Indian Promoters | % | 48.3 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 75.0 | - | |
| Indian inst/Mut Fund | % | 6.9 | 7.9 | 87.3% | |
| FIIs | % | 34.4 | 0.1 | 34,400.0% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.5 | 17.1 | 61.4% | |
| Shareholders | 56,727 | 18,270 | 310.5% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare GLENMARK PHARMA With: SANOFI INDIA TORRENT PHARMA FRESENIUS KABI ONCO. CIPLA GSK PHARMA
Compare GLENMARK PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)
In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.
Related Views on News
GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 5, 2019 | Updated on Sep 5, 2019Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)
Jun 3, 2019 | Updated on Jun 3, 2019For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)
May 28, 2019 | Updated on May 28, 2019For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsMost Popular
Could this Smallcap Be the Next Page Industries?(Profit Hunter)
Nov 27, 2019A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)
Nov 25, 2019This one trade had my subscribers laughing all the way to the bank.
Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)
Nov 28, 2019Should you invest in growth stocks or value stocks to make strong returns in this market?
Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)
Nov 26, 2019The two trends that are playing out as Sensex touches new record high.
The Best Trading Strategy for Fast Profits
Nov 29, 2019Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.
MoreGLENMARK PHARMA SHARE PRICE
Dec 6, 2019 03:31 PM
TRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA 8-QTR ANALYSIS
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.